439 related articles for article (PubMed ID: 21235429)
1. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
2. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.
Manousaridis I; Mavridou S; Goerdt S; Leverkus M; Utikal J
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):11-8. PubMed ID: 22540151
[TBL] [Abstract][Full Text] [Related]
4. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
5. MEK inhibitors in oncology: a patent review (2015-Present).
Mahapatra DK; Asati V; Bharti SK
Expert Opin Ther Pat; 2017 Aug; 27(8):887-906. PubMed ID: 28594589
[TBL] [Abstract][Full Text] [Related]
6. [Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].
Baldini C; Duchemann B; Hollebecque A; Routier É; Varga A; Gazzah A; Bahleda R; Besse B; Soria JC; Massard C
Bull Cancer; 2012 Sep; 99(9):865-74. PubMed ID: 25471668
[TBL] [Abstract][Full Text] [Related]
7. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
8. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
10. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
11. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
12. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
13. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
14. Current Development Status of MEK Inhibitors.
Cheng Y; Tian H
Molecules; 2017 Sep; 22(10):. PubMed ID: 28954413
[TBL] [Abstract][Full Text] [Related]
15. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
16. Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C; Settleman J
Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
[TBL] [Abstract][Full Text] [Related]
17. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Favre G
Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II RAF kinase inhibitors in cancer therapy.
Turajlic S; Ali Z; Yousaf N; Larkin J
Expert Opin Investig Drugs; 2013 Jun; 22(6):739-49. PubMed ID: 23642225
[TBL] [Abstract][Full Text] [Related]
19. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
20. MEK inhibitors under development for treatment of non-small-cell lung cancer.
Kim C; Giaccone G
Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
